Risk factors associated with adverse fetal outcomes in pregnancies affected by Coronavirus disease 2019 (COVID-19): a secondary analysis of the WAPM study on COVID-19.

Data de publicació:

Autors de IIS La Fe

Autors aliens a IIS La Fe

  • Di Mascio D
  • Sen C
  • Saccone G
  • Galindo A
  • Grünebaum A
  • Yoshimatsu J
  • Stanojevic M
  • Kurjak A
  • Chervenak F
  • Rodríguez Suárez MJ
  • Gambacorti-Passerini ZM
  • Baz MLAA
  • Aguilar Galán EV
  • López YC
  • De León Luis JA
  • Hernández IC
  • Herraiz I
  • Villalain C
  • Venturella R
  • Rizzo G
  • Mappa I
  • Gerosolima G
  • Hellmeyer L
  • Königbauer J
  • Ameli G
  • Frusca T
  • Volpe N
  • Luca Schera GB
  • Fieni S
  • Esposito E
  • Simonazzi G
  • Di Donna G
  • Youssef A
  • Della Gatta AN
  • Di Donna MC
  • Chiantera V
  • Buono N
  • Sozzi G
  • Greco P
  • Morano D
  • Bianchi B
  • Lombana Marino MG
  • Laraud F
  • Ramone A
  • Cagnacci A
  • Barra F
  • Gustavino C
  • Ferrero S
  • Ghezzi F
  • Cromi A
  • Laganà AS
  • Laurita Longo V
  • Stollagli F
  • Sirico A
  • Lanzone A
  • Driul L
  • Cecchini D F
  • Xodo S
  • Rodriguez B
  • Mercado-Olivares F
  • Elkafrawi D
  • Sisti G
  • Esposito R
  • Coviello A
  • Cerbone M
  • Morlando M
  • Schiattarella A
  • Colacurci N
  • De Franciscis P
  • Cataneo I
  • Lenzi M
  • Sandri F
  • Buscemi R
  • Gattei G
  • Sala FD
  • Valori E
  • Rovellotti MC
  • Done E
  • Faron G
  • Gucciardo L
  • Esposito V
  • Vena F
  • Giancotti A
  • Brunelli R
  • Muzii L
  • Nappi L
  • Sorrentino F
  • Vasciaveo L
  • Liberati M
  • Buca D
  • Leombroni M
  • Di Sebastiano F
  • Di Tizio L
  • Gazzolo D
  • Franchi M
  • Ianniciello QC
  • Garzon S
  • Petriglia G
  • Borrello L
  • Nieto-Calvache AJ
  • Burgos-Luna JM
  • Kadji C
  • Carlin A
  • Bevilacqua E
  • Moucho M
  • Pinto PV
  • Figueiredo R
  • Jimenez Lopez JS
  • Aykanat AY
  • Cosma S
  • Carosso A
  • Benedetto C
  • Bermejo A
  • May Feuerschuette OH
  • Uyaniklar O
  • Ocakouglu SR
  • Atak Z
  • Gündüz R
  • Haberal ET
  • Froessler B
  • Parange A
  • Palm P
  • Samardjiski I
  • Taccaliti C
  • Okuyan E
  • Daskalakis G
  • Moreira de Sa RA
  • Pittaro A
  • Gonzalez-Duran ML
  • Guisan AC
  • Genç SÖ
  • Zlatohlávková B
  • Piqueras AL
  • Oliva DE
  • Cil AP
  • Api O
  • Antsaklis P
  • Ples L
  • Kyvernitakis I
  • Maul H
  • Malan M
  • Lila A
  • Granese R
  • Ercoli A
  • Zoccali G
  • Villasco A
  • Biglia N
  • Madalina C
  • Costa E
  • Daelemans C
  • Pintiaux A
  • Cueto E
  • Hadar E
  • Dollinger S
  • Brzezinski Sinai NA
  • Huertas E
  • Arango P
  • Sanchez A
  • Schvartzman JA
  • Cojocaru L
  • Turan S
  • Turan O
  • Di Dedda MC
  • Molpeceres RG
  • Zdjelar S
  • Premru-Srsen T
  • Cerar LK
  • Druškovic M
  • De Robertis V
  • Stefanovic V
  • Nupponen I
  • Nelskylä K
  • Khodjaeva Z
  • Gorina KA
  • Sukhikh GT
  • Maruotti GM
  • Visentin S
  • Cosmi E
  • Ferrari J
  • Gatti A
  • Luvero D
  • Angioli R
  • Puri L
  • Palumbo M
  • D'Urso G
  • Colaleo F
  • Chiara Rapisarda AM
  • Carbone IF
  • Mollo A
  • Nazzaro G
  • Locci M
  • Guida M
  • Di Spiezio Sardo A
  • Panici PB
  • Berghella V
  • Flacco ME
  • Manzoli L
  • Bifulco G
  • Scambia G
  • Zullo F
  • D'Antonio F

Grups d'Investigació

Abstract

Objectives To evaluate the strength of association between maternal and pregnancy characteristics and the risk of adverse perinatal outcomes in pregnancies with laboratory confirmed COVID-19. Methods Secondary analysis of a multinational, cohort study on all consecutive pregnant women with laboratory-confirmed COVID-19 from February 1, 2020 to April 30, 2020 from 73 centers from 22 different countries. A confirmed case of COVID-19 was defined as a positive result on real-time reverse-transcriptase-polymerase-chain-reaction (RT-PCR) assay of nasal and pharyngeal swab specimens. The primary outcome was a composite adverse fetal outcome, defined as the presence of either abortion (pregnancy loss before 22 weeks of gestations), stillbirth (intrauterine fetal death after 22 weeks of gestation), neonatal death (death of a live-born infant within the first 28 days of life), and perinatal death (either stillbirth or neonatal death). Logistic regression analysis was performed to evaluate parameters independently associated with the primary outcome. Logistic regression was reported as odds ratio (OR) with 95% confidence interval (CI). Results Mean gestational age at diagnosis was 30.6±9.5 weeks, with 8.0% of women being diagnosed in the first, 22.2% in the second and 69.8% in the third trimester of pregnancy. There were six miscarriage (2.3%), six intrauterine device (IUD) (2.3) and 5 (2.0%) neonatal deaths, with an overall rate of perinatal death of 4.2% (11/265), thus resulting into 17 cases experiencing and 226 not experiencing composite adverse fetal outcome. Neither stillbirths nor neonatal deaths had congenital anomalies found at antenatal or postnatal evaluation. Furthermore, none of the cases experiencing IUD had signs of impending demise at arterial or venous Doppler. Neonatal deaths were all considered as prematurity-related adverse events. Of the 250 live-born neonates, one (0.4%) was found positive at RT-PCR pharyngeal swabs performed after delivery. The mother was tested positive during the third trimester of pregnancy. The newborn was asymptomatic and had negative RT-PCR test after 14 days of life. At logistic regression analysis, gestational age at diagnosis (OR: 0.85, 95% CI 0.8-0.9 per week increase; p<0.001), birthweight (OR: 1.17, 95% CI 1.09-1.12.7 per 100 g decrease; p=0.012) and maternal ventilatory support, including either need for oxygen or CPAP (OR: 4.12, 95% CI 2.3-7.9; p=0.001) were independently associated with composite adverse fetal outcome. Conclusions Early gestational age at infection, maternal ventilatory supports and low birthweight are the main determinants of adverse perinatal outcomes in fetuses with maternal COVID-19 infection. Conversely, the risk of vertical transmission seems negligible.

Dades de la publicació

ISSN/ISSNe:
0300-5577, 1619-3997

JOURNAL OF PERINATAL MEDICINE  WALTER DE GRUYTER GMBH

Tipus:
Article
Pàgines:
950-958
PubMed:
32975205
Factor d'Impacte:
0,688 SCImago
Quartil:
Q2 SCImago

Cites Rebudes en Web of Science: 88

Documents

  • No hi ha documents

Mètriques

Filiacions mostrar / ocultar

Keywords

  • Coronavirus, perinatal morbidity, perinatal mortality

Projectes associats

APLICACION DE TECNICAS LAPLACIANAS PARA LA MONITORIZACION DE LA ACTIVIDAD ELECTRICA DEL MUSCULO LISO HUMANO:ENFASIS EN ELECTROHISTEROGRAMA (LAMOHIS)

Investigador Principal: ALFREDO JOSÉ PERALES MARÍN

LAMOHIS PLAN NACIONAL I+D+I 2008-2011 . 2010

UTILIDAD DEL TRATAMIENTO TOCOLITICO DE MANTENIMIENTO EN EL MANEJO DE LA AMENAZA DE PARTO PREMATURO (APP)

Investigador Principal: MÁXIMO VENTO TORRES

EC11-246 . 2012

RED DE SALUD MATERNO INFANTIL Y DEL DESARROLLO

Investigador Principal: MÁXIMO VENTO TORRES

RD12/0026/0012 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2013

PAPEL DEL FACTOR DE CRECIMIENTO PLACENTARIO EN EL MANEJO DE LA PREECLAMPSIA NO SEVERA: ESTUDIO ALEATORIZADO

Investigador Principal: ALFREDO JOSÉ PERALES MARÍN

PI15/01935 . INSTITUTO DE SALUD CARLOS III . 2016

Iplacenta. innovation in pacenta modelling for maternal and fetal health.

Investigador Principal: JOSÉ MORALES ROSELLÓ

765274 . COMISION EUROPEA . 2018

Variaciones epigenómicas asociadas al inicio y curso de los trastornos del neurodesarrollo en prematuros: estudio de cohorte a 6 años.

Investigador Principal: ANA CRISTINA GARCÍA BLANCO

PI18/01352 . INSTITUTO DE SALUD CARLOS III . 2019

ELECTROHISTEROGRAFÍA PARA LA MEJORA EN LA TOMA DE DECISIONES EN SITUACIONES DE RIESGO EN OBSTETRICIA: PARTO PREMATURO E INDUCCIÓN DEL PARTO (EHG-TD-OBST).

Investigador Principal: YIYAO YE LIN

RTI2018-094449-A-I00 . 2018

ESTUDIO PROSPECTIVO, DE SEGUIMIENTO, DE NIÑOS DE 23 A 25 MESES, NACIDOS DE MADRES QUE RECIBIERON CAPROATO DE HIDROXIPROGESTERONA INYECTABLE, 250 MG/ML O VEHICULO, PARA LA PREVENCION DEL PARTO PREMATURO.

Investigador Principal: ALFREDO JOSÉ PERALES MARÍN

17P-FU-004 . 2012

ESTUDIO OBSERVACIONAL, MULTICÉNTRICO, PROSPECTIVO, ABIERTO, PARA EVALUAR LA SEGURIDAD DE NIFE-PAR® EN EL TRATAMIENTO DE LA AMENAZA DE PARTO PRETÉRMINO.

Investigador Principal: VICENTE JOSE DIAGO ALMELA

REI-NIF-2016-01 . 2017

ENSAYO MULTICÉNTRICO, ABIERTO, ALEATORIZADO, DE DOSIS ÚNICA, CONTROLADO, DE XOMA 213 ADMINISTRADO POR VÍA INTRAVENOSA A MUJERES DESPUÉS DEL PARTO PARA LA SUPRESIÓN DE LA LACTANCIA.

Investigador Principal: ALFREDO JOSÉ PERALES MARÍN

X213220

Compartir la publicació